Nasal spray could quickly calm anxiety in End-of-Life patients
NCT ID NCT06330584
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether a midazolam nasal spray can quickly reduce acute anxiety in adults receiving palliative care. Participants will receive one of two doses of midazolam or a placebo spray. The main goal is to see if anxiety levels drop within 30 minutes, while also checking safety and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
midazolam nasal spray
What this could lead to
If it works, this could offer a fast, needle-free way to calm severe anxiety in people receiving end-of-life care.
What could go wrong
This is a very small early pilot study with only 36 participants, so results may not apply broadly. Midazolam can cause drowsiness or breathing problems, especially in frail patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANXIETY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Inselspital, Universitätsspital Bern
NOT_YET_RECRUITINGBern, 3010, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kompetenzzentrum Palliative Care, Universitätsspital Zürich
RECRUITINGZurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Palliativzentrum Bethesda Spital
RECRUITINGBasel, Canton of Basel-City, 4052, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitäres Zentrum für Palliative Care (UZP)
RECRUITINGBern, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zentrum für Palliative Care, Stadtspital Zürich
RECRUITINGZurich, 8037, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••